Abstract: A method and system for monitoring a packet network by using call detail records (CDRs) are disclosed. The method first receives at least one call detail record (CDR) at a completion of a call from at least one voice gateway router that serviced said call and analyzes said at least one CDR. The method then monitors at least one performance parameter in accordance with said at least one CDR.

Abstract: A method and system for monitoring a packet network by using call detail records (CDRs) are disclosed. The method first receives at least one call detail record (CDR) at a completion of a call from at least one voice gateway router that serviced said call and analyzes said at least one CDR. The method then monitors at least one performance parameter in accordance with said at least one CDR.

Abstract: Compounds of formula: (1) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.

Abstract: A backrest for a vehicle seat includes a backrest frame, which is surrounded by a cover and has an upper backrest with an adjustable inclination. An additional frame is hinged so as to be pivotable about a pivot axis to a side plate, the cover, or the backrest frame. The pivot axis is arranged in an upper region of the backrest, and the additional frame extends upwards from the pivot axis in the installed position of the backrest. The additional frame can be secured in different angular positions in relation to the backrest frame, and, thus, a variable gap forms between the additional cover of the additional frame and the cover of the backrest frame.

Abstract: The application relates to novel 2-azetidinone derivatives of formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof. The compounds are cholesterol absorption inhibitors and are useful in the treatment of hyperlipidaemic conditions, including atherosclerosis, Alzheimers' disease and cholesterol associated tumours. The application also relates to pharmaceutical formulations comprising such compounds and to processes for their preparation.

Abstract: The invention relates to novel 2-azetidinone derivatives of formula (I) and to pharmaceutically acceptable salts, solvates and prodrugs thereof. The compounds are cholesterol absorption inhibitors, useful in the treatment of hyperlipidaemic conditions. The invention also relates to processes for their manufacture and to pharmaceutical compositions containing them.

Abstract: The present invention relates to imidazopyridine derivatives of the Formula I and, therapeutically acceptable salts thereof which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the treatment of gastrointestinal inflammatory diseases. In further aspects, the invention relates to the compound of the invention for use in therapy; to processes for preparation of such new compound; to pharmaceutical compositions containing the compound of the invention, or a therapeutically acceptable salt thereof, as active ingredient; and to the use of the compound of the invention in the manufacture of medicaments for the medical use indicated above.

Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts, solvates, and prodrugs thereof, and to their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia. The invention also relates to processes for their manufacture and pharmaceutical compositions containing them.

Abstract: The invention relates to 2-azetidinone derivatives of formula (I), including pharmaceutically acceptable salts, solvates and prodrugs thereof. The compounds inhibit cholesterol absorption and are useful in the treatment of hyperlipidaemic conditions. The invention also relates to processes for their manufacture and to pharmaceutical compositions containing them.

Abstract: A backrest for a vehicle seat includes a backrest frame, which is surrounded by a cover and has an upper backrest with an adjustable inclination. An additional frame is hinged so as to be pivotable about a pivot axis to a side plate, the cover, or the backrest frame. The pivot axis is arranged in an upper region of the backrest, and the additional frame extends upwards from the pivot axis in the installed position of the backrest. The additional frame can be secured in different angular positions in relation to the backrest frame, and, thus, a variable gap forms between the additional cover of the additional frame and the cover of the backrest frame.

Abstract: Compounds of formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described.

Abstract: The present invention relates to novel crystalline forms of 2,3-dimethyl-8-(2,6 -dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt and to mixture thereof. Further, the present invention also relates to processes for obtaining them, the use of said compounds for the treatment of gastrointestinal disorders, and pharmaceutical compositions containing them.

Abstract: Compounds of formula (I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders and to pharmaceutical compositions containing them.

Abstract: A method of producing a material including agglomerated particles of precipitated silica, including preparing a solution of at least two metal salts (Me), wherein the metal ions are divalent or polyvalent. A solution of alkali metal (M) silicate having a molar ratio SiO2/M2O of 1-4 is prepared. The solutions are mixed and the mixture stirred, allowing a coagulum to immediately form. The coagulum is rinsed, collected, dewatered, impregnated and processed to provide a material having a dry matter content of >75%, preferably >97%. A material obtainable by the process is also provided.

Abstract: The present invention relates to compounds of formula (I): wherein Rv, R1, R2, Rx, Ry, R3, R4, R5, R6, Rz and v are as defined within; pharmaceutically acceptable salts, solvates, solvates or such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.

Abstract: The present invention relates to novel crystalline forms of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt and to mixture thereof. Further, the present invention also relates to processes for obtaining them, the use of said compounds for the treatment of gastrointestinal disorders, and pharmaceutical compositions containing them.

Abstract: The present invention relates to imidazo pyridine derivatives of the Formula I which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastric acid related diseases or gastrointestinal inflammatory diseases.

Abstract: The present invention relates to compounds of formula (I), wherein variable groups are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia.

Abstract: The present invention relates to novel compounds, and therapeutically acceptable salts thereof of the formula (I), which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.

Abstract: The present invention relates to compounds of formula (1): wherein Rv, R1, R2, Rx, Ry, R3, R4, R5, R6, Rz and v are as defined within; pharmaceutically acceptable salts, solvates, solvates or such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.